Safety of Pioglitazone for Hematoma Resolution In Intracerebral Hemorrhage
Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
Intracerebral hemorrhage (ICH) is a devastating disease with less than 20% of survivors being
independent at 6 months. There is currently no approved treatment for ICH which has been
shown to improve outcomes. In an effort to develop a new treatment for ICH, this research
focuses on a different aspect of ICH treatment which has not yet been evaluated: enhancing
absorption of the blood clot with medication.
Phase:
Phase 2
Details
Lead Sponsor:
The University of Texas Health Science Center, Houston